These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11762642)

  • 21. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
    Lansiaux A; Facompré M; Wattez N; Hildebrand MP; Bal C; Demarquay D; Lavergne O; Bigg DC; Bailly C
    Mol Pharmacol; 2001 Sep; 60(3):450-61. PubMed ID: 11502875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
    Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of new homocamptothecin analogs.
    Luo Y; Yu S; Tong L; Huang Q; Lu W; Chen Y
    Eur J Med Chem; 2012 Aug; 54():281-6. PubMed ID: 22647222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
    Lavergne O; Harnett J; Rolland A; Lanco C; Lesueur-Ginot L; Demarquay D; Huchet M; Coulomb H; Bigg DC
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2599-602. PubMed ID: 10498216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
    Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
    Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
    Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
    Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
    Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insilico analysis of homocamptothecin (hCPT) analogues for anti-tumour activity.
    Vadwai V; Devaraj S
    Int J Bioinform Res Appl; 2009; 5(6):603-15. PubMed ID: 19887335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
    Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homocamptothecins: E-ring modified CPT analogues.
    Lavergne O; Demarquay D; Kasprzyk PG; Bigg DC
    Ann N Y Acad Sci; 2000; 922():100-11. PubMed ID: 11193885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lamellarin D: a novel potent inhibitor of topoisomerase I.
    Facompré M; Tardy C; Bal-Mahieu C; Colson P; Perez C; Manzanares I; Cuevas C; Bailly C
    Cancer Res; 2003 Nov; 63(21):7392-9. PubMed ID: 14612538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
    Aiba K; Funakoshi S; Mizunuma N; Dobashi N; Hirano A; Sano M; Kuraishi Y; Kamada M; Ohno N; Sugimoto Y
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1601-6. PubMed ID: 8060134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
    Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
    Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
    Chauvier D; Morjani H; Manfait M
    Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
    J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology of camptothecin and its derivatives].
    Rivory LP; Robert J
    Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.